• About
    • Our Company
    • Contact
  • Science
    • PIKA Technology Platform
  • Pipeline
    • Our Pipeline
    • Product Candidate
      • Infectious Disease
      • Immuno-Oncology Biotherapeutics
    • Commercial Products
  • Business Development
    • Partnerships
  • Investor Relations
    • Overview
    • News & Events
      • News Releases
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
    • Governance
      • Documents & Charters
      • Board of Directors
      • Management
      • Committee Composition
    • Financials & Filings
      • SEC Filings
    • Resources
      • Investor FAQs
      • Email Alerts
      • Information Request
      • Contact IR
  • Career
    • Working at Yisheng
Menu
  • About
    • Our Company
    • Contact
  • Science
    • PIKA Technology Platform
  • Pipeline
    • Our Pipeline
    • Product Candidate
      • Infectious Disease
      • Immuno-Oncology Biotherapeutics
    • Commercial Products
  • Business Development
    • Partnerships
  • Investor Relations
    • Overview
    • News & Events
      • News Releases
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
    • Governance
      • Documents & Charters
      • Board of Directors
      • Management
      • Committee Composition
    • Financials & Filings
      • SEC Filings
    • Resources
      • Investor FAQs
      • Email Alerts
      • Information Request
      • Contact IR
  • Career
    • Working at Yisheng

YS Biopharma Received Qualified Person Declaration for Its PIKA COVID-19 Vaccine Facility from European Union GMP

  • November 15, 2022
  • yisheng
  • 2022
Gaithersburg, Maryland, November 15, 2022 /PRNewswire/ — YS Biopharma Co., Ltd. (“YS Biopharma” or the “Company”), a global biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations...
Continue Reading

YS Biopharma Announces US FDA Clearance Of IND Application For PIKA COVID-19 vaccine

  • November 10, 2022
  • yisheng
  • 2022
Gaithersburg, Maryland, November 10, 2022 /PRNewswire/ — YS Biopharma Co., Ltd. (“YS Biopharma” or the “Company”), a global biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations...
Continue Reading

YS BIOPHARMA TO MERGE WITH NASDAQ-LISTED SUMMIT HEALTHCARE ACQUISITION CORP.

  • September 29, 2022
  • yisheng
  • 2022
• Transaction values YS Biopharma at pre-money equity value of $834 million • Certain investors (“Forward Purchase Investors”) are expected to invest $30 million in a private placement concurrently...
Continue Reading

YishengBio Received Approvals From Philippines and UAE For Phase 2 / 3 Clinical Trials of PIKA Recombinant COVID-19 vaccine

  • September 8, 2022
  • yisheng
  • 2022
Beijing, China – September 8, 2022 – YishengBio Co., Ltd., (“YishengBio”), a biopharmaceutical company dedicated to discovery, development, manufacturing and commercialization of new generations of vaccines and therapeutic biologics,...
Continue Reading

YishengBio Raises $130 Million in Series B Funding to Accelerate Pipeline Development and Commercialization

  • February 24, 2021
  • yisheng
  • 2022
Beijing, China – February 24, 2021 – YishengBio Co., Ltd. (“YishengBio”, the “Company”) announced today the closing of a US$130 million in Series B funding round. The new investment...
Continue Reading

Search

Recent Posts

  • YS Biopharma Received Qualified Person Declaration for Its PIKA COVID-19 Vaccine Facility from European Union GMP
  • YS Biopharma Announces US FDA Clearance Of IND Application For PIKA COVID-19 vaccine
  • YS BIOPHARMA TO MERGE WITH NASDAQ-LISTED SUMMIT HEALTHCARE ACQUISITION CORP.
  • YishengBio Received Approvals From Philippines and UAE For Phase 2 / 3 Clinical Trials of PIKA Recombinant COVID-19 vaccine
  • A New Therapeutic Vaccine Successfully Developed Against Rabies

Recent Comments

    Archives

    • November 2022
    • September 2022
    • June 2021
    • May 2021
    • February 2021

    Categories

    • 2022
    • Press Release
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    Site MapTerms of UsePrivacy

    Contact Info

    YS Biopharma Co., Ltd.

    11 Firstfield Road Suite A
    Gaithersburg, Maryland 20878 USA

    Tel: +1 (301) 208 8823
    Fax: +1 (301) 208 8827

    bjinfo@yishengbio.com

    Copyright © 2021 Yisheng Biopharma. All Rights Reserved.